A generic process template for continuous pharmaceutical production by Singh, Ravendra et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
A generic process template for continuous pharmaceutical production
Singh, Ravendra; Rozada-Sanches, Raquel; Dean, William ; Perkins, Jacob; Muller, Frans; Godfrey,
Andy; Gernaey, Krist V.; Gani, Rafiqul; Woodley, John
Published in:
Proceedings of the 11th International Symposium on Process Systems Engineering
Publication date:
2012
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Singh, R., Rozada-Sanches, R., Dean, W., Perkins, J., Muller, F., Godfrey, A., ... Woodley, J. (2012). A generic
process template for continuous pharmaceutical production. In I. A. Karimi, & R. Srinivasan (Eds.), Proceedings
of the 11th International Symposium on Process Systems Engineering (pp. 715-719). Elsevier Science.
(Computer - Aided Chemical Engineering, Vol. 31).
A generic process template for continuous pharmaceutical production  
Ravendra Singha,b, Raquel Rozada-Sanchezc, William Deanc, Jacob Perkinsc, Frans 
Mullerc, Andy Godfreyc , Krist V. Gernaeya, Rafiqul Ganib and John M. Woodleya* 
aPROCESS, Department of Chemical and Biochemical Engineering, Technical 
University of Denmark, DK-2800 Lyngby, Denmark 
bCAPEC, Department of Chemical and Biochemical Engineering, Technical University 
of Denmark, DK-2800 Lyngby, Denmark 
cAstraZeneca Limited, Charter Way, Silk Road Business Park, Macclesfield, Cheshire 
SK10 2NA, UK 
In most of the manufacturing industry (and in particular in the pharmaceutical industry), 
one of the prime objectives is to be fast in the development of new processes, such that 
it is possible to be first to launch new products on the market. Identification of an 
effective and safe pharmaceutical product is based on success in clinical trials. Often, 
several candidate compounds targeting the same disease area are tested in order to 
identify efficacious products. This involves the manufacture of small quantities of 
compounds in  early delivery campaigns. Of these candidates only a few will be 
successful such that further development is required to scale–up the process. 
Conventionally, for each product candidate a unique process needs to be developed. 
However, the development of a specific process for each product candidate is costly in 
terms of time and resources. Therefore, a generic process template is needed that can be 
adapted for production of a series of similar products for the early delivery campaigns, 
resulting in a significant reduction of time, early manufacturing cost and resource 
consumption. A generic process template can be defined as a standard process format 
able to be adapted for a series of similar substrates. 
In the work reported here, a generic continuous process template for pharmaceutical 
production involving nitro reduction has been developed. The developed process 
template can be adapted for a series of nitro compounds (substrates). To assist in 
adoption of different substrates, a systematic substrate adoption methodology (SAM) is 
also presented. The generic process template together with the SAM provides a 
flexibility similar to batch processes as well as an efficiency similar to continuous 
processes. It also reduces inventory for a safer operation (from 50 to 100 L in batch to 3 
to 5 L in continuous process).  The generic process template will potentially reduce the 
process development time and therefore supports shortening time to market for a given 
compound. In addition to SAM, other methods and tools that support the manufacturing 
concept proposed in this work contribute to making it flexible and fast to implement 
(e.g. a graphical tool for determining a suitable operating window and property 
prediction methods and tools).  
The objective of this presentation is two-fold: First to highlight the value of a generic 
process template and the associated methods and tools, and second to demonstrate its 
application using a pharmaceutical case study involving a nitro reduction. 
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